« PreviousNext »Journal of the American Academy of Dermatology
Volume 63, Issue 3 , Pages 457-465, September 2010
Volume 63, Issue 3 , Pages 457-465, September 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
To access this article, please choose from the options below
Supported by Centocor, Inc.
Disclosures can be found in the Appendix.
PII: S0190-9622(09)01197-9
doi:10.1016/j.jaad.2009.09.014
© 2009 American Academy of Dermatology, Inc. Published by Elsevier Inc All rights reserved.
« PreviousNext »Journal of the American Academy of Dermatology
Volume 63, Issue 3 , Pages 457-465, September 2010
Volume 63, Issue 3 , Pages 457-465, September 2010
